Patent · US Active

Anti-PD-1/LAG3 bispecific antibodies

US11072658B2 · kind B2 · utility

2Cited by
17References
19Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJan 31, 2019
Grant dateJul 27, 2021
Priority date
Expiry dateMar 31, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.